Author

TAIGO KATO

Observed name: Taigo Kato

Institution: The University of Osaka

Observed institution: The University of Osaka

OpenAlex ID: A5146674044

SLFN11 Drives GM-CSF–mediated M1 Macrophage Polarization and Enhances Immunotherapy Response in Renal Cell Carcinoma

2026 · YOHEI OKUDA, JUNKO MURAI, et al. · Anticancer Research · 1

Neutrophil-to-lymphocyte ratio and performance status are associated with increased risk of skin toxicity in patients receiving enfortumab vedotin with or without pembrolizumab for metastatic urothelial carcinoma

2026 · Yujiro Hayashi, Atsunari Kawashima, et al. · Cancer Treatment and Research Communications · 1

Peripheral B-cell receptor repertoire predicts immune-related adverse events following immune checkpoint inhibitor therapy in advanced renal cell carcinoma

2026 · Akihiro Yoshimura, Taigo Kato, et al. · Scientific Reports

Short-term outcomes of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: Real-world use in multicenter cohort regardless of cisplatin eligibility

2026 · Takuji Hayashi, Atsunari Kawashima, et al. · Research Square

The number of dissected lymph nodes contributes to good prognosis after robot-assisted radical cystectomy for muscle-invasive bladder cancer without lymph node metastasis at clinical staging

2026 · Takuji Hayashi, Atsunari Kawashima, et al. · Research Square

Works count: 5

Citation count: 2

H-index: 1

I10-index: